Experimental HIV Drugs
Experimental HIV Drugs
CROI 2013: Pipeline Antiretrovirals Promise More Effective and Better Tolerated HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
New antiretroviral drugs and treatment strategies are no longer the predominant focus of the annual Conference on Retroviruses and Opportunistic Infections (CROI), but this year's meeting included several presentations on refinements to HIV therapy that offer the prospect of greater efficacy -- especially for people with resistant virus -- fewer side effects, and more convenient administration.
CROI 2013: Development of Small Molecules for HIV Eradication [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Gregory Fowler
Research towards a cure for HIV is a key theme of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), taking place this week in Atlanta. One of the many approaches under study is the use of small molecules to bring resting HIV out of latency, in an effort to ultimately eradicate the virus from the body.
ViiV Announces Halt to Lersivirine Development
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.
Dolutegravir Active against Raltegravir-resistant HIV, Granted FDA Priority Review
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 February 2013 00:00
- Written by Liz Highleyman
ViiV Healthcare announced last week that the U.S. Food and Drug Administration has given a priority review designation for its investigational HIV integrase inhibitor dolutegravir, which has demonstrated good efficacy in both treatment-naive and treatment-experienced people.
New HIV NNRTI Lersivirine Matches Efavirenz in Phase 2b Trial
- Details
- Category: HIV Treatment
- Published on Friday, 01 February 2013 00:00
- Written by Liz Highleyman
The investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine suppressed HIV viral load as well as efavirenz (Sustiva) in a 48-week trial, but with a different and side effect profile, researchers reported in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes.
More Articles...
- Gilead Starts Phase 3 Trials for New HIV Pro-drug Tenofovir Alafenamide
- Lancet: Dolutegravir Works as Well as Raltegravir for First-time HIV Treatment
- ViiV Submits Integrase Inhibitor Dolutegravir for Approval in the U.S., Europe, and Canada
- Coverage of 11th International Congress on Drug Therapy in HIV Infection
Web Design and Development by